All In Biotech

NDA 017648 · Baxter Hlthcare

Sodium Chloride 0.9% and Potassium Chloride 0.075%

Potassium Chloride, Sodium Chloride · Injection

Last checked: Nov 19, 2026Latest source record: Jan 11, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Feb 2, 1979

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

60

44 serious, 10 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 11, 2019.

INDICATIONS AND USAGE Potassium Chloride in Sodium Chloride Injection, USP is indicated as a source of water and electrolytes.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 2, 1979 Original approval · Type 5 - New Formulation or New Manufacturer Letter
5 products under this application
  • SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% · POTASSIUM CHLORIDE 75MG/100ML; SODIUM CHLORIDE 900MG/100ML · INJECTABLE, INJECTION · Discontinued
  • POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% · POTASSIUM CHLORIDE 300MG/100ML; SODIUM CHLORIDE 900MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% · POTASSIUM CHLORIDE 150MG/100ML; SODIUM CHLORIDE 450MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9% · POTASSIUM CHLORIDE 224MG/100ML; SODIUM CHLORIDE 900MG/100ML · INJECTABLE, INJECTION · Discontinued
  • POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% · POTASSIUM CHLORIDE 150MG/100ML; SODIUM CHLORIDE 900MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypokalaemia10
  • acute kidney injury9
  • dehydration7
  • crohn^s disease6
  • diarrhoea6
  • international normalised ratio increased6
  • pelvic fluid collection6
  • pulmonary embolism6
  • dyspnoea5
  • sepsis5
  • vomiting5
  • atrial fibrillation4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20121
20135
20143
20153
20165
201710
20183
201910
20207
20217
20222
20231
20242

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Baxter Hlthcare · Also marketed as Potassium Chloride 0.3% and Sodium Chloride 0.9%, Potassium Chloride 0.15% In Sodium Chloride 0.45%, Potassium Chloride 0.224% In Sodium Chloride 0.9%, Potassium Chloride 0.15% In Sodium Chloride 0.9%

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.